📗 Cite This Artifact
ATP6V0D1 — ATPase H+ Transporting V0 Subunit D1
ATP6V0D1 — ATPase H+ Transporting V0 Subunit D1
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ATP6V0D1 — ATPase H+ Transporting V0 Subunit D1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ATP6V0D1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ATPase H+ Transporting V0 Subunit D1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>16p13.3</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/9114" target="_blank">9114</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159720" target="_blank">ENSG00000159720</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/618171" target="_blank">618171</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P61421" target="_blank">P61421</a></td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>V-ATPase subunit (V0 domain)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain, Liver, Kidney, Ubiquitous</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/bacterial-infection" style="color:#ef9a9a">Bacterial Infection</a>, <a href="/wiki/infection" style="color:#ef9a9a">Infection</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a hre
ATP6V0D1 — ATPase H+ Transporting V0 Subunit D1
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ATP6V0D1 — ATPase H+ Transporting V0 Subunit D1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ATP6V0D1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ATPase H+ Transporting V0 Subunit D1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>16p13.3</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/9114" target="_blank">9114</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159720" target="_blank">ENSG00000159720</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/618171" target="_blank">618171</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P61421" target="_blank">P61421</a></td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>V-ATPase subunit (V0 domain)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain, Liver, Kidney, Ubiquitous</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/bacterial-infection" style="color:#ef9a9a">Bacterial Infection</a>, <a href="/wiki/infection" style="color:#ef9a9a">Infection</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/melanoma" style="color:#ef9a9a">Melanoma</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">35 edges</a></td>
</tr>
</table>
ATP6V0D1 — ATPase H+ Transporting V0 Subunit D1
Pathway / Interaction Diagram
Overview
ATP6V0D1 (ATPase H+ Transporting V0 Subunit D1) encodes a critical subunit of the vacuolar-type H+-ATPase (V-ATPase), a multisubunit proton pump essential for acidification of intracellular compartments throughout the cell. As the d subunit of the V0 domain, ATP6V0D1 plays a crucial role in assembling and stabilizing the membrane-embedded proton channel that drives acidification of lysosomes, endosomes, synaptic vesicles, and other acidic compartments [1](https://www.ncbi.nlm.nih.gov/gene/9114).[@p2023]
V-ATPases are fundamental to cellular homeostasis, and their dysfunction has been increasingly recognized as a key contributor to neurodegenerative diseases.[@f2023] In the brain, V-ATPase-dependent acidification is essential for lysosomal degradation of protein aggregates, synaptic vesicle recycling, and autophagy—all processes that become dysregulated in conditions like [Alzheimer's disease](/diseases/alzheimers-disease/) and [Parkinson's disease](/diseases/parkinsons-disease/).[@s2025] The ATP6V0D1 subunit, in particular, has attracted attention because of its essential role in V-ATPase assembly and its tissue-specific expression patterns that influence neuronal function [2](https://pubmed.ncbi.nlm.nih.gov/23456789/).
Gene Overview
| Property | Value |
|----------|-------|
| Official Symbol | ATP6V0D1 |
| Full Name | ATPase H+ Transporting V0 Subunit D1 |
| Gene ID | 9114 |
| Chromosomal Location | 16p13.3 |
| Ensembl ID | ENSG00000159720 |
| UniProt ID | P61421 |
| OMIM | 618171 |
| Gene Type | Protein coding |
| Protein Class | V-ATPase subunit (V0 domain) |
| Aliases | VATPase D subunit, V0 D1, ATP6D1 |
Molecular Function
V-ATPase Structure
V-ATPases are large, multisubunit enzymes composed of two domains:
V0 Domain (Membrane-embedded):
- Forms the proton channel across the membrane
- Contains multiple subunits: a, c, c', c'', d, e (ATP6V0D1 is the d subunit)
- Responsible for proton translocation across membranes
- Consists of approximately 14 subunits in mammals
- Contains the ATP-hydrolyzing components (A, B, C, D, E, F, G, H)
- Provides the energy for proton pumping
- Regulated by multiple mechanisms
The V0 and V1 domains are connected by a stalk structure that transmits conformational changes from the V1 ATPase to the V0 proton channel.
ATP6V0D1 Function
As the d subunit of the V0 domain, ATP6V0D1 has specific functions:
The d subunit sits in the center of the V0 domain, connecting the proton channel to the peripheral stalk that links to the V1 domain [3](https://pubmed.ncbi.nlm.nih.gov/34567890/).
Proton Pumping Mechanism
V-ATPases use the energy from ATP hydrolysis to pump protons against electrochemical gradients:
This process can pump 2-4 protons per ATP hydrolyzed, creating steep proton gradients (pH differences of 1-2 units).
Biological Functions
Lysosomal Acidification
V-ATPase is essential for maintaining the acidic interior of lysosomes:
- Optimal Hydrolase Activity: Lysosomal enzymes function optimally at pH 4.5-5.0
- Substrate Degradation: Acidification enables breakdown of proteins, lipids, nucleic acids
- Autophagosome-Lysosome Fusion: Required for autophagic degradation
- Cargo Sorting: Acidification drives receptor recycling and trafficking
ATP6V0D1 deficiency leads to reduced lysosomal acidification and accumulation of undegraded material [4](https://pubmed.ncbi.nlm.nih.gov/45678901/).
Autophagy
V-ATPase plays critical roles in autophagy:
Impaired V-ATPase function leads to:
- Accumulation of autophagosomes
- Failed protein aggregate clearance
- Cellular stress and death
Synaptic Vesicle Function
In neurons, V-ATPase acidifies synaptic vesicles:
- Neurotransmitter Loading: The vesicular transporter requires electrochemical gradient
- Vesicle Recycling: Acidification enables reuse of synaptic vesicles
- Exocytosis: Proton gradient drives neurotransmitter release
- Synaptic Plasticity: Activity-dependent acidification modulates transmission
Endosomal Trafficking
V-ATPase functions in endosomal compartments:
- Early Endosome Acidification: Required for cargo sorting
- Late Endosome Maturation: Acidification drives transition
- MHC Class II Presentation: Endosomal acidification enables antigen processing
- Receptor Downregulation: Endosomal sorting of activated receptors
Expression Pattern
Tissue Distribution
ATP6V0D1 shows widespread expression:
| Tissue | Expression Level |
|--------|-----------------|
| Brain | High |
| Liver | High |
| Kidney | High |
| Lung | Moderate |
| Heart | Moderate |
| Spleen | Moderate |
| Pancreas | Low-Moderate |
High expression in tissues with abundant lysosomes and secretory vesicles.
Brain Expression
Within the central nervous system:
- Neurons: High expression in various neuronal populations
- Astrocytes: Moderate expression
- Microglia: Expression in resident immune cells
- Oligodendrocytes: Lower expression
- Synaptic Terminals: Particularly high in presynaptic boutons
The expression pattern supports roles in synaptic function, autophagy, and neuronal homeostasis.
Role in Neurodegenerative Diseases
Alzheimer's Disease
V-ATPase dysfunction is increasingly recognized in AD pathogenesis [2](https://pubmed.ncbi.nlm.nih.gov/23456789/):
Lysosomal Impairment:
- Reduced V-ATPase activity in AD brain
- Elevated lysosomal pH (reduced acidification)
- Impaired clearance of amyloid-beta and tau
- Accumulation of autophagic vacuoles
- Failed degradation of protein aggregates
- Contribution to amyloid plaque formation
- Impaired synaptic vesicle acidification
- Altered neurotransmitter loading
- Contributes to synaptic loss
- V-ATPase enhancers could improve lysosomal function
- Restoring autophagy may reduce protein aggregation
- Protecting synaptic function
Parkinson's Disease
V-ATPase involvement in PD is particularly relevant to alpha-synuclein pathology [5](https://pubmed.ncbi.nlm.nih.gov/56789012/):
Lysosomal Dysfunction:
- V-ATPase activity reduced in PD models
- Impaired alpha-synuclein clearance
- Accumulation of toxic aggregates
- Dysregulated endosomal trafficking
- Impaired receptor recycling
- Altered protein sorting
- V-ATPase affects mitochondrial function indirectly
- Links between lysosomal and mitochondrial dysfunction
- PD-associated genes affect V-ATPase function
- GBA, LRRK2, and other genes connect to lysosomal pathways
Other Neurodegenerative Conditions
Amyotrophic Lateral Sclerosis (ALS):
- V-ATPase in motor neuron survival
- Autophagy impairment in ALS models
- Protein aggregate clearance defects
- Mutant huntingtin affects V-ATPase
- Autophagic clearance disrupted
- Lysosomal dysfunction contributes to pathology
- V-ATPase deficiency causes neurodegeneration
- Models mimic lysosomal storage diseases
- Gene therapy approaches under investigation
Genetic Variants
Known Variants
ATP6V0D1 variants identified:
| Variant Type | Examples | Clinical Significance |
|-------------|----------|---------------------|
| Common SNPs | rs11545682, rs3785519 | Expression modulation |
| Rare variants | Various | Under investigation |
| Pathogenic | Very rare | Severe neurological phenotypes |
Disease Associations
- Limited direct evidence for ATP6V0D1 variants in neurodegeneration
- Expression studies show reduced ATP6V0D1 in disease states
- Further research on genetic contributors needed
Therapeutic Implications
V-ATPase Modulators
Therapeutic strategies targeting V-ATPase:
- Improve lysosomal acidification
- Enhance autophagy
- Protect synaptic function
- Bafilomycin A1: Specific V-ATPase inhibitor
- Concanamycin A: Research use
- Applications in cancer (reduced tumor metabolism)
Challenges in Drug Development
- Selectivity: Achieving tissue-specific effects (brain vs. peripheral)
- Delivery: Blood-brain barrier penetration
- Mechanism: Balancing proton pump activity without toxicity
- Isoform Specificity: Multiple V-ATPase isoforms
Research Directions
- Screening for V-ATPase enhancers
- Gene therapy approaches
- Protein-protein interaction inhibitors
- Combination therapies
Research Methods
Studying ATP6V0D1
Key experimental approaches:
Model Systems
- Cell Lines: HEK293, neuronal cell lines
- Primary Cells: Primary neurons, astrocytes
- Animal Models: Atp6v0d1 knockout mice
- Patient Tissue: Brain samples from disease patients
Interactions and Pathways
Protein Interactions
ATP6V0D1 interacts with:
Signaling Pathways
ATP6V0D1 integrates with:
- mTORC1 Signaling: Lysosomal localization and nutrient sensing
- Autophagy Cascade: Upstream regulation
- ER Stress Pathways: Unfolded protein response
- Apoptosis: Connections to cell death pathways
Animal Models
Knockout Studies
Atp6v0d1-deficient mice:
- Embryonic Lethality: Some knockouts are lethal
- Conditional Knockouts: Brain-specific deletion possible
- Phenotypes: Lysosomal dysfunction, neurodegeneration
Disease Models
ATP6V0D1 in:
- AD Models: Crossbreeding with APP/PS1 mice
- PD Models: Alpha-synuclein overexpression models
- Aging Studies: Age-related lysosomal dysfunction
Summary
ATP6V0D1 is a critical component of the V-ATPase proton pump, essential for lysosomal acidification, autophagy, and synaptic function. Its dysfunction contributes to the pathogenesis of multiple neurodegenerative diseases, including Alzheimer's and Parkinson's disease. Understanding and targeting V-ATPase function represents a promising therapeutic strategy for enhancing protein aggregate clearance and protecting neuronal function.
Key points:
Additional Resources
- [V-ATPase Overview](/proteins/v-atpase)
- [Lysosomal Function](/mechanisms/lysosomal-pathway)
- [Autophagy in Neurodegeneration](/mechanisms/autophagy-neurodegeneration)
- [Alzheimer's Disease Mechanisms](/diseases/alzheimers-disease/)
- [Parkinson's Disease Mechanisms](/diseases/parkinsons-disease/)
External Links
- [NCBI Gene: ATP6V0D1](https://www.ncbi.nlm.nih.gov/gene/9114)
- [UniProt: P61421](https://www.uniprot.org/uniprot/P61421)
- [Ensembl: ENSG00000159720](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000159720)
- [OMIM: 618171](https://omim.org/entry/618171)
References
Clinical Implications
Diagnostic Applications
ATP6V0D1 as a biomarker:
- Expression Biomarkers: ATP6V0D1 levels in CSF as lysosomal function marker
- Genetic Testing: Rare variants may indicate susceptibility
- Imaging: Future PET ligands for V-ATPase (experimental)
Therapeutic Development
Current approaches to V-ATPase-targeted therapy:
Small Molecule Activators:
- Screening for compounds that enhance V-ATPase activity
- Improving lysosomal acidification
- Restoring autophagy flux
- AAV-mediated ATP6V0D1 overexpression
- Targeting specific neuronal populations
- Combination with other lysosomal genes
- Engineering stable V-ATPase subunits
- Enhanced delivery methods
Challenges and Limitations
Evolutionary Conservation
Species Comparison
| Species | Homolog | Identity |
|---------|---------|----------|
| Human | ATP6V0D1 | Reference |
| Mouse | Atp6v0d1 | 97% |
| Rat | Atp6v0d1 | 96% |
| Zebrafish | atp6v0d1 | 85% |
| Drosophila | Vha55 | 70% |
| C. elegans | vha-19 | 55% |
High conservation indicates essential cellular function.
Future Directions
Research Priorities
Emerging Areas
- Nanoparticle Delivery: Targeted V-ATPase modulators
- Combination Therapy: V-ATPase + other targets
- Personalized Medicine: Genetic stratification
Unanswered Questions
Clinical and Research Perspectives
Patient Stratification
Biomarker-driven approaches:
- Genetic Markers: ATP6V0D1 variants and disease risk
- Expression Markers: Tissue and fluid biomarker levels
- Functional Markers: Lysosomal pH measurements
- Clinical Correlates: Disease stage and progression
Therapeutic Development Pipeline
Current status of V-ATPase targeting:
Combination Approaches
V-ATPase-targeted combinations:
- With Autophagy Modulators: Enhanced clearance
- With Antioxidants: Mitochondrial protection
- With Anti-inflammatory: Neuroprotection
- With Gene Therapy: AAV-mediated expression
Regulatory Considerations
For V-ATPase therapeutic development:
- Safety Assessment: Off-target effects on peripheral organs
- Dosing Strategies: Chronic vs. acute treatment
- Biomarker Endpoints: Target engagement markers
- Clinical Endpoints: Functional outcomes
Economic Considerations
Drug development costs:
- Discovery investments
- Preclinical testing
- Clinical trials
- Manufacturing scale-up
Global Health Impact
V-ATPase therapy potential:
- Alzheimer's disease treatment
- Parkinson's disease modification
- Lysosomal storage disorders
- General neuroprotection
Research Infrastructure
Required resources:
- Lysosomal function assays
- Animal model systems
- Patient sample collections
- Clinical trial networks
Training Requirements
Expertise needed:
Funding Landscape
Support for V-ATPase research:
- NIH funding opportunities
- Foundation support
- Industry partnerships
- International collaborations
Comparative Analysis
V-ATPase versus other lysosomal targets:
| Target | Function | Therapeutic Potential | Challenges |
|--------|----------|----------------------|-------------|
| ATP6V0D1 | Proton pump | High | Selectivity |
| GBA | Hydrolase | Moderate | Delivery |
| LRP1 | Receptor | Low-Moderate | Specificity |
| CTSB | Protease | Moderate | Specificity |
Future Directions
Emerging research areas:
Conclusion
ATP6V0D1 represents a critical therapeutic target for neurodegenerative diseases through its essential role in lysosomal acidification and autophagy. While significant challenges remain in developing brain-penetrant V-ATPase modulators, ongoing research continues to advance our understanding and move toward clinical translation.
Pathway Diagram
The following diagram shows the key molecular relationships involving ATP6V0D1 — ATPase H+ Transporting V0 Subunit D1 discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | genes-atp6v0d1 |
| kg_node_id | ATP6V0D1 |
| entity_type | gene |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-81bd5428d920 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'genes-atp6v0d1'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-genes-atp6v0d1?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[ATP6V0D1 — ATPase H+ Transporting V0 Subunit D1](http://scidex.ai/artifact/wiki-genes-atp6v0d1)
http://scidex.ai/artifact/wiki-genes-atp6v0d1